Failed study shows need for esophageal cancer biomarkers
Categories
The addition of cetuximab to concurrent chemoradiation failed to improve survival in patients with esophageal cancer, according to results from the randomized, multicenter NRG-RTOG 0436 phase 3 trial.
https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/in-the-journals/%7Ba941dd78-c7a3-4182-a603-65763a0b313b%7D/failed-study-shows-need-for-esophageal-cancer-biomarkers